Related Experiment Video
Updated: Jul 4, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
Phospholipase D1 is an effector of Rheb in the mTOR pathway
1Department of Cell and Developmental Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Abstract:
The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for Rheb activation of the mTOR pathway, as demonstrated by the effects of RNAi. The overexpression of Rheb activates PLD1 in cells in the absence of mitogenic stimulation, and the knockdown of Rheb impairs serum stimulation of PLD activation. Furthermore, the overexpression of TSC2 suppresses PLD1 activation, whereas the knockdown or deletion of TSC2 leads to elevated basal activity of PLD. Consistent with a TSC-Rheb-PLD signaling cascade, AMPK and PI3K, both established regulators of TSC2, appear to lie upstream of PLD as revealed by the effects of pharmacological inhibitors, and serum activation of PLD is also dependent on amino acid sufficiency. Finally, Rheb binds and activates PLD1 in vitro in a GTP-dependent manner, strongly suggesting that PLD1 is a bona fide effector for Rheb. Hence, our findings reveal an unexpected interaction between two cascades in the mTOR signaling pathways and open up additional possibilities for targeting this important growth-regulating network for the development of anticancer drugs.
Insights
This study reveals Phospholipase D1 (PLD1) is essential for Rheb-mediated activation of the mTOR pathway, a key target in cancer therapy. Findings uncover a novel TSC-Rheb-PLD signaling cascade, offering new therapeutic strategies.
Area of Science:
- Cell Biology
- Molecular Biology
- Biochemistry
Background:
- The mammalian target of rapamycin (mTOR) pathway regulates cell growth and is a critical target for anticancer therapies.
- Upstream regulators of mTOR include the tuberous sclerosis complex (TSC1/2) proteins, the small GTPase Rheb, and Phospholipase D (PLD).
- The integration of TSC/Rheb and PLD signaling pathways within the mTOR network remains largely unexplored.
Purpose of the Study:
- To investigate the interaction and integration between the TSC/Rheb and PLD pathways in the context of mTOR signaling.
- To determine the specific role of PLD isoforms (PLD1 and PLD2) in Rheb-mediated mTOR activation.
- To elucidate the upstream regulators and downstream effectors within this newly proposed signaling cascade.
Main Methods:
- RNA interference (RNAi) to assess the requirement of PLD1 and PLD2 in Rheb-mTOR signaling.
- Overexpression and knockdown studies of Rheb and TSC2 to evaluate their impact on PLD1 activity.
- Pharmacological inhibition of AMPK and PI3K to identify upstream regulators of the TSC-Rheb-PLD pathway.
- In vitro binding assays to confirm the direct interaction between Rheb and PLD1.
Main Results:
- PLD1, but not PLD2, is required for Rheb to activate the mTOR pathway.
- Rheb overexpression activates PLD1, while Rheb knockdown impairs serum-stimulated PLD activation.
- TSC2 overexpression suppresses PLD1 activation; TSC2 loss increases basal PLD activity, supporting a TSC-Rheb-PLD cascade.
- AMPK, PI3K, and amino acid sufficiency are upstream regulators of PLD activation.
- Rheb directly binds and activates PLD1 in a GTP-dependent manner, identifying PLD1 as a Rheb effector.
Conclusions:
- Phospholipase D1 (PLD1) is a direct effector of Rheb and a crucial component of the mTOR signaling pathway.
- A novel TSC-Rheb-PLD signaling cascade is identified, integrating previously separate regulatory pathways upstream of mTOR.
- These findings provide new insights into mTOR regulation and suggest potential therapeutic targets for anticancer drug development.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
IP3/DAG Signaling Pathway

